


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354

Final Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Bayer (acoramidis)	All Wales Inherited Metabolic Disease Service
Patient/carer groups	All Wales Therapeutics and Toxicology
Addenbrookes Liver Transplant	Centre
Association	Allied Health Professionals Federation
Amyloidosis UK	Association of Renal Industries
Arrythmia Alliance	Board of Community Health Councils in
Atrial Fibrillation Association	Wales
British Liver Trust	British National Formulary
Cardiomyopathy UK	Care Quality Commission
Cardiovascular Care Partnership	Cell and Gene Therapy Catapult
Circulation Foundation	Department of Health, Social Services
Gene People	and Public Safety for Northern Ireland
Genetic Alliance UK	Healthcare Improvement Scotland
HEART UK	Medicines and Healthcare products
Kidney Research UK	Regulatory Agency
LIVErNORTH	National Association of Primary Care National Blazza and Association
Liver4Life	National Pharmacy Association
Pumping Marvellous	National Services Division
Somerville Foundation	NHS Confederation
South Asian Health Foundation	NHS Wales Joint Commissioning Committee
Specialised Healthcare Alliance	0 (() 1 M () 1 0 ()
 Healthcare professional groups Association for Inherited Cardiac 	Scottish Society of Gastroenterology Walso Nauralagical Alliance
Conditions	Wales Neurological AllianceWelsh Government
A	• Weish Government
A ' (' CO (' N)	Comparator companies
Association of Genetic Nurses and Counsellors	Pfizer (tafamidis)
Association of Renal Technologists	- Theory (caramato)
 British Association for the Study of the 	Relevant research groups
Liver	Brain Research UK
British Association of Endocrine and Thyroid Surgeons	Cochrane Hepato-Biliary Group
Thyrold odrycons	



Consultees	Commentators (no right to submit or appeal)
 British Association of Urological Nurses British Association of Urological Surgeons British Cardiovascular Society British Geriatrics Society British Neuropathological Society British Nuclear Cardiology Society British Nuclear Cardiology Society British Society for Gene and Cell Therapy British Society for Genetic Medicine British Society for Haematology British Society for Haematology British Society of Cardiovascular Magnetic Resonance British Society of Echocardiography British Society of Gastroenterology British Society of Paediatric Gastroenterology, Hepatology and Nutrition Haemochromatosis UK Institute of Neurology National Heart and Lung Institute National Metabolic Biochemistry Network National Neuroscience Advisory Group Neuromodulation Society of UK and Ireland Primary Care and Community Neurology Society Primary Care Cardiovascular Society Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association 	 Cochrane Metabolic & Endocrine Disorders Group Foundation for Liver Research Genomics England MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Hospital for Neurology and Neurosurgery National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency



Consultees	Commentators (no right to submit or appeal)
 Vascular Society of Great Britain and Ireland 	
 Others National Amyloidosis Centre, UCL Department of Health and Social Care NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).





All non-company commentators are invited to nominate clinical or patient experts.